Close
Help
Login
Staff Login
Register
0
Selected
Invert selection
Deselect all
Deselect all
Add to Cart
Click here to refresh results
Click here to refresh results
Go to Login page
AstraZeneca blood clot risk remains low: Tam
AstraZeneca blood clot risk remains low: Tam
AstraZeneca blood clot risk remains low: Tam
Standard Video
Actions
Overview
Conceptually Similar Documents
CP121635062 | AstraZeneca vaccine to remain authorized in Canada
CP122404571 | Quebec reports first blood clot death in woman who received AstraZeneca vaccine
CP124397371 | AstraZeneca recipients can get Moderna or Pfizer for second dose: NACI
CP123262421 | N.S. pauses use of AstraZeneca vaccine
CP123597771 | Second-dose choice likely for AstraZeneca recipients: Tam
CP120476771 | AstraZeneca vaccine's benefits vastly outweigh risks: Sharma
CP122830710 | New Brunswick reports blood clot death in connection with Oxford-AstraZeneca vaccine
CP123251321 | Ontario to get more than 250,000 AstraZeneca doses
CP122904771 | B.C. records first case of rare blood clot related to vaccine
CP123774871 | Ontario to resume AstraZeneca shots for COVID-19 as second dose
City
Vaughan
Country
Canada
Add to cart
Select usage
Type of video?
For editorial use only. Video needs to be used in its entirety (i.e. use of select segment(s) not allowed).
Audience Size
Usage description
Add to collection
Add to cart
AstraZeneca blood clot risk remains low: Tam
Source name:
The Canadian Press
Unique identifier:
CP122017117
Legacy Identifier:
n_Tam-NACI-Vaccine20210421T1430
Type:
Video
Duration:
3m17s
Dimensions:
1920px × 1080px 143.31 MB
Usage rights:
FOR ONE TIME USE ONLY. NO STORAGE FOR FUTURE USE.
Create Date:
4/21/2021 2:30:00 PM
Display aspect ratio:
16:9
Tags
AstraZeneca
NACI
Theresa Tam